Tradestie Institutional Equity Comparison Engine

LABT vs ADVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ADVB Overall Edge

ADVB Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Advanced Biomed Inc. Common Stock (ADVB) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, LABT trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ADVB at N/M Forward P/E and -4883.8% operating margin (+0.0% YoY). In options structure, LABT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ADVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LABT N/M vs ADVB N/M Fwd P/E
Growth & Margin Winner ADVB
Op Margin N/A vs -4883.8% ยท YoY N/A vs +0.0%
Momentum & Technical Winner ADVB
1Y -97.2% vs +299.2% ยท 52W Pos 1% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
LABT US Equity
LABT
Institutional Equity
$0.24
+15.03% 1D
Market Cap N/A
1M Return -49.97%
1Y Return -97.17%
Forward P/E N/M
Unified AI Score
47.5 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 64.0
ADVB NASDAQ
Advanced Biomed Inc. Common Stock
Services-Medical Laboratories
$1.65
-5.71% 1D
Market Cap $2.9M
1M Return -52.31%
1Y Return +299.23%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LABT -97.17% ADVB +299.23% Spread: +22.67 pp (ADVB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LABT TTM Op. Margin: N/A ADVB TTM Op. Margin: -4883.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LABT vs ADVB. Trailing 12-month operating profitability (LABT N/A vs ADVB -4883.8%) and valuation multiples (LABT N/M vs ADVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LABT (1) vs ADVB (7)
Institutional Metric LABT ADVB Criterion Row Winner
Market Capitalization Scale N/A $2.9M Larger Scale ADVB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth ADVB
Operating Margin (TTM) Profitability N/A -4883.8% Higher Margin ADVB
Net Profit Margin Profitability N/A 5231.3% Higher Margin ADVB
Return on Equity (ROE) Capital Efficiency N/A -79.5% Higher ROE ADVB
52-Week Range Position Momentum 1% ($0โ€“$10) 6% ($0โ€“$24) Stronger Trend ADVB
Beta / 30D Volatility Risk Regime -8.45ฮฒ ยท 672% Vol 0.26ฮฒ ยท 216% Vol Lower Realized Risk ADVB
Unified Institutional Score Composite Signal 47.5 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite LABT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LABT vs ADVB Buy Guide
LABT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LABT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ADVB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ADVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LABT nor ADVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.